Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label

Oncologic Drugs Advisory Committee says totality of evidence supports licensure of CT-P10 for three lymphoma indications, but panelists question what additional data would be needed to eventually get Rituxan’s other approved uses, which were carved out for patent and exclusivity reasons, onto the biosimilar’s label.

FDA Advisory Committee Feature image

A US FDA advisory committee unanimously endorsed the approval of Celltrion Inc.'s CT-P10, but the sponsor’s request for a limited label had panelists questioning the implications for the biosimilar’s use in other indications for which the reference product, Genentech Inc.’s Rituxan, is approved.

On Oct. 10, the Oncologic Drugs Advisory Committee voted 16-0 that the totality of evidence supports licensure of CT-P10 as...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers